This category covers peptides and related signaling compounds studied for their influence on metabolic regulation, mitochondrial function, and energy utilization within cells. Research often focuses on pathways affecting glucose metabolism, lipid oxidation, thermogenesis, and mitochondrial efficiency. These compounds are frequently explored in contexts involving metabolic flexibility, body composition regulation, energy expenditure, and cellular energy signaling networks.
SLU-PP-332 is an ERR agonist research compound discussed around exercise-mimetic biology, mitochondrial signaling, and metabolic models.
SLU-PP-332 sits in the Aeternus peptide library as a current performance-biology research topic, not as a conventional peptide. The useful public framing is that it is a small-molecule estrogen-related receptor agonist studied for exercise-mimetic and metabolic signaling effects in preclinical systems. That makes it relevant to mitochondrial and performance discussions, but it also requires unusually clear boundaries.
SLU-PP-332 is described in the reviewed literature as a synthetic agonist for estrogen-related receptors, a nuclear receptor family involved in energy metabolism, mitochondrial gene expression, and skeletal-muscle oxidative programs. It is not a peptide in the structural sense. It appears in this library because it is part of the same public conversation around performance compounds, metabolic signaling, and exercise-mimetic research.
The biological context centers on ERR signaling, skeletal muscle transcription, mitochondrial oxidative capacity, fatty-acid oxidation, and energy-balance models. Those systems overlap with endurance adaptation and metabolic flexibility, which explains the interest. The boundary is that a transcriptional or animal-model response is not the same as a demonstrated human training outcome.
SLU-PP-332 is discussed through estrogen-related receptor activation, especially ERR-alpha-linked transcriptional programs. The reviewed ACS Chemical Biology work supports a mechanism-level discussion around an acute aerobic exercise-like transcriptional response and mouse exercise-capacity models. The right interpretation is mechanistic and preclinical: ERR activation can organize energy-metabolism signals, but it does not prove human performance benefit.
The metabolic-syndrome model literature adds context around energy expenditure, fatty-acid oxidation, insulin-sensitivity endpoints, and fat-mass findings in mice. Those endpoints are useful for understanding why the compound is studied, but they should not be translated into weight-loss, endurance, or metabolic-health promises. Aeternus keeps the mechanism in its lane: biologically interesting, source-supported, and not a substitute for direct human evidence.
Human data. The reviewed sources do not include direct human outcome studies on SLU-PP-332. Human-facing language should therefore remain limited to research orientation and should not imply established safety, predictable performance effects, or validated metabolic outcomes in people.
Preclinical data. Most of the useful evidence is preclinical. The reviewed mouse and cell-model work supports discussion of ERR signaling, skeletal-muscle transcription, energy expenditure, metabolic-syndrome models, and exercise-capacity endpoints. Those findings support biological plausibility, not human translation.
Anecdotal discussion. Anecdotal discussion around SLU-PP-332 often follows the phrase exercise mimetic. That phrase can explain public interest, but it should not set the claim standard. Anecdote and online performance discussion do not establish product identity, safety, durability, or real-world outcomes.
Not a human performance validation. Mouse exercise-capacity and metabolic endpoints can explain why SLU-PP-332 is studied, but they do not establish predictable human training, body-composition, or endurance outcomes.
Not a peptide-equivalent biology story. SLU-PP-332 belongs here as a current library topic, but it is a small-molecule ERR agonist rather than a peptide. Public content should say that clearly.
Analytical context matters. The doping-control literature supports caution around performance-use framing and product identity, not casual access or practical use claims.
Long-term safety remains unresolved. The reviewed sources do not establish durable human safety, population fit, or risk profile.
Human exposure data remains limited. The reviewed safety context does not support casual or unsupervised framing, especially for a compound discussed in performance and exercise-mimetic settings.
Regulatory and sport-governance context matters. WADA and analytical-source context should be treated as a reason to avoid performance-use language and to keep the entry educational.
Product identity matters. Public conversation around emerging compounds can move faster than source quality, and names can detach from verified material, purity, and oversight.
SLU-PP-332 shows up in performance discussions because exercise-mimetic biology is an attractive idea. The public temptation is to compress that idea into a shortcut claim. A more disciplined reading is that the compound helps illustrate how researchers study transcriptional pathways related to training adaptation, energy use, and metabolic regulation.
For an Aeternus reader, the practical value is interpretation. SLU-PP-332 can be understood as a research probe that points toward mitochondrial and metabolic signaling questions. It should not be framed as a training replacement, a body-composition solution, or a verified tool for human performance.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
Not a training replacement. SLU-PP-332 should not be presented as a substitute for training, nutrition, sleep, or recovery discipline.
Not a validated human performance tool. The current evidence does not support assured endurance, metabolism, or body-composition claims.
Not a conventional peptide. It belongs in this library as a current compound topic, but its biology is ERR agonism, not peptide signaling.
Not a protocol or personal-use guide. This entry is educational only and should not be read as direction for unsupervised use.
Aeternus treats SLU-PP-332 as a high-interest but evidence-limited performance-biology topic. The responsible position is to explain ERR signaling, mitochondrial context, and preclinical exercise-mimetic findings while refusing shortcut claims. The compound belongs in an evidence-aware conversation about mechanism and limits, not in a promise-driven conversation about human results.
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.
Retatrutide is an investigational triple incretin agonist studied in human metabolic trials, with claims limited to trial context.
Retatrutide is one of the more evidence-visible entries in the current library because it has published human clinical research. That does not make it a casual wellness peptide or an approved consumer compound. It is best framed as an investigational triple-hormone-receptor agonist with metabolic trial data, defined adverse-event context, and unresolved long-term questions.
Retatrutide, also known in earlier literature as LY3437943, is designed to engage GIP, GLP-1, and glucagon receptor pathways. Those pathways influence appetite regulation, glucose handling, energy balance, and metabolic signaling. The compound belongs in a clinical research context, not a personal-use or optimization context.
The biological context centers on incretin signaling, appetite and satiety biology, glucose regulation, body-weight research endpoints, hepatic fat research, and cardiometabolic risk markers. That makes the topic highly relevant to metabolic medicine, but the evidence still has to be read by trial population, endpoint, duration, adverse events, and investigational status.
Retatrutide is discussed mechanistically as a triple agonist involving GIP, GLP-1, and glucagon receptor pathways. GLP-1 biology is commonly associated with appetite, gastric emptying, and glucose-dependent insulin signaling. GIP and glucagon signaling add additional metabolic complexity, which is why the compound is studied as more than a single-pathway incretin agent.
The mechanism should not be turned into a promise. Multi-receptor design can explain why clinical researchers are interested in body-weight, glycemic, and liver-fat endpoints, but it does not establish individual results, long-term safety, or broad access. The responsible public framing is trial-specific and investigational.
Human data. The reviewed references include human clinical studies, including early type 2 diabetes research, a phase 2 obesity trial, and phase 2a metabolic-liver research. These sources support human evidence discussion. They also require narrow wording because the endpoints, populations, duration, adverse events, and investigational status define what can be said.
Preclinical data. The main public evidence base for this entry is human clinical research rather than animal-model support. Mechanistic rationale can be discussed through incretin and glucagon receptor biology, but the profile should prioritize direct human trial context and avoid implying broader outcomes than the studies measured.
Anecdotal discussion. Anecdotal discussion around retatrutide often focuses on weight change and comparisons to other incretin agents. That discussion may explain public interest, but it should not set the claim standard. Company updates, online reports, and expectations for future availability are not the same as peer-reviewed, final clinical evidence.
Trial context controls the claim. Human findings should be limited by study population, endpoint, duration, comparator, and adverse-event profile.
Investigational status matters. Retatrutide should not be described as approved medicine or as a consumer option.
Long-term outcomes remain unresolved. Phase 3 and longer follow-up evidence are needed before broader conclusions can be made.
Company topline updates are not the same as final peer-reviewed evidence. They can inform status context but should not replace published trial interpretation.
Adverse-event context matters. Human trial evidence should be summarized with attention to tolerability and reported adverse events rather than only efficacy endpoints.
Regulatory status matters. Retatrutide remains investigational, and unapproved incretin-related products require cautious public language.
Personal-use framing is inappropriate. This entry should not encourage unsupervised access, product sourcing, or individual metabolic decisions.
Retatrutide shows up in performance and health discussions because metabolic health, appetite regulation, body composition, and energy balance are central to long-term resilience. The compound should not be framed as a physique shortcut or a wellness trend. It is a clinical research topic with meaningful but bounded human evidence.
The practical interpretation is to separate trial data from public speculation. Published phase 1b, phase 2, and metabolic-liver research can be summarized, but the page should avoid translating study findings into advice, access expectations, or outcome promises for individuals.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
Not approved medicine. Retatrutide should be described as investigational unless approval status changes and is verified.
Not a weight-loss promise. Trial endpoints do not guarantee individual outcomes or long-term real-world results.
Not a consumer optimization peptide. The evidence belongs in clinical research context, not casual wellness framing.
Not a protocol or personal-use guide. This entry is educational only and should not be read as direction for unsupervised use.
Aeternus views retatrutide as a high-evidence but high-responsibility library entry. The human trial data makes it more substantial than many peptide topics, while the investigational status and safety context require restraint. The right public position is precise and clinical: explain the triple-receptor biology, summarize the evidence by study type, and avoid turning trial findings into personal outcomes.
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.
Tesamorelin is a GHRH analog with approved medical-use context and endocrine-metabolic relevance that requires precise framing.
Tesamorelin is different from many entries in the peptide library because it has an approved medical-use context. That does not mean public content should become personal guidance. The responsible profile explains the growth-hormone-releasing hormone pathway, the defined clinical context, and the safety and limitation boundaries without turning an approval into broad optimization language.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, often abbreviated GHRH. It is designed to stimulate the pituitary growth-hormone axis in a regulated clinical context. Because that endocrine pathway touches body composition, metabolic markers, and hormone signaling, the entry requires careful separation between approved-use context, research endpoints, and public wellness claims.
The biological context centers on the GHRH-growth-hormone axis, IGF-1 response, visceral adipose tissue research, metabolic markers, endocrine feedback, and population-specific clinical evaluation. Those systems are powerful enough that casual language is inappropriate. The topic belongs in an evidence-aware clinical context, not a broad anti-aging or performance context.
Tesamorelin works through GHRH analog biology, engaging the pituitary pathway that regulates growth-hormone release and downstream IGF-1 signaling. That mechanism is clinically meaningful, but it also carries endocrine complexity. Public content should describe the axis without implying that more activity is automatically better.
The reviewed clinical literature supports discussion of visceral adipose tissue endpoints in a defined HIV lipodystrophy context and related safety monitoring. That is a narrow evidence lane. It should not be generalized into broad body-composition, longevity, recovery, or performance claims.
Human data. The reviewed references include human clinical evidence and FDA labeling context. That supports a strong human-data classification for the defined approved-use and study settings. It does not support broad claims outside the studied population, endpoint, and clinical oversight context.
Preclinical data. Preclinical mechanism can help explain GHRH and endocrine-axis biology, but this entry should primarily rely on human clinical and regulatory sources. The key evidence distinction is not animal versus human; it is approved, population-specific clinical context versus unsupported generalization.
Anecdotal discussion. Anecdotal discussion around tesamorelin often focuses on body composition, aging, and hormone optimization. That discussion should remain secondary. Endocrine compounds can be misrepresented when public narratives detach from labeling, monitoring, contraindication, and study-population limits.
Approved context is not universal context. Evidence should be limited to the labeled and studied clinical setting unless new sources support broader claims.
Endocrine markers require caution. Growth-hormone and IGF-1 signaling are not simple wellness levers and should not be framed casually.
General body-composition claims are risky. The reviewed evidence does not justify broad physique or anti-aging promises.
Safety monitoring matters. Public content should keep adverse-event, contraindication, and oversight context visible.
Regulatory status matters. FDA labeling supports a defined medical context, not a general optimization frame.
Endocrine risk context matters. Pituitary, growth-hormone, and IGF-1 signaling require careful review and should not be simplified into benefit language.
Public language should avoid broad body-composition promises. Clinical endpoints in a defined population do not establish casual use claims.
Tesamorelin appears in performance and longevity conversations because growth-hormone signaling is culturally linked to body composition, recovery, and aging. That public association is exactly why the entry needs disciplined language. Endocrine signaling is not a casual optimization theme.
The practical interpretation should focus on evidence boundaries. Tesamorelin can be explained as an approved medicine in a specific context and as a research topic for endocrine-metabolic outcomes. It should not be presented as a general peptide for physique, anti-aging, or recovery goals.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
Not a general anti-aging peptide. Tesamorelin should not be framed as a broad longevity, recovery, or physique tool.
Not a casual hormone optimizer. GHRH and growth-hormone signaling require clinical context and careful interpretation.
Not proof for every body-composition claim. Defined clinical endpoints do not validate broad consumer claims.
Not a protocol or personal-use guide. This entry is educational only and should not be read as direction for unsupervised use.
Aeternus views tesamorelin as a clinically important peptide topic that needs precision rather than excitement. The approved medical-use context makes the evidence base more concrete, while the endocrine pathway makes overreach more consequential. The right entry explains the GHRH axis, names the defined evidence lane, keeps safety visible, and avoids turning medical context into optimization marketing.
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.
NAD+ is a cellular redox and energy-metabolism topic tied to mitochondrial biology, aging research, and human precursor studies.
NAD+ is not a niche peptide, but it is central to the same performance and longevity conversations that surround many peptide entries. It is a coenzyme involved in redox metabolism, mitochondrial function, DNA-repair signaling, and sirtuin biology. The responsible framing is that NAD+ biology is foundational, while intervention claims require careful evidence separation.
NAD+ stands for nicotinamide adenine dinucleotide. It cycles between oxidized and reduced states and helps transfer electrons in cellular energy metabolism. It also participates in signaling systems involving sirtuins, PARPs, CD38, and cellular stress response. Because NAD+ is biologically important, public claims often run ahead of direct evidence.
The biological context centers on redox metabolism, mitochondrial energy production, DNA-repair signaling, aging biology, circadian and stress-response pathways, and metabolic resilience. Those systems are interconnected, which makes NAD+ a legitimate educational topic. It also means simple claims about energy, longevity, or rejuvenation should be avoided.
NAD+ supports oxidation-reduction reactions and acts as a substrate for enzymes that influence cellular stress signaling. In mitochondria, NAD+/NADH balance is central to energy metabolism. In signaling biology, NAD+-consuming enzymes connect metabolic state to repair, inflammation, and aging-research pathways.
The reviewed human precursor literature supports discussion of NAD+-related biomarker changes in certain contexts. That is useful, but it is not the same as proving that NAD+ intervention produces broad longevity, performance, or disease outcomes. Mechanism should frame the research question, not answer every public claim.
Human data. The reviewed sources include human research and review-level evidence around NAD+ precursors and pharmacokinetic or biomarker endpoints. This supports human evidence discussion, but the claims should remain tied to what was measured rather than broad longevity or performance outcomes.
Preclinical data. Preclinical aging and mitochondrial literature provides the mechanistic backbone for NAD+ interest. Animal and cell studies help explain pathways involving redox state, sirtuins, PARPs, and mitochondrial function. They do not establish direct human rejuvenation or performance effects.
Anecdotal discussion. Anecdotal discussion around NAD+ often centers on energy, recovery, clarity, and anti-aging. Those themes explain visibility, but they are weak evidence. Subjective reports should remain secondary to controlled human data, mechanism, safety context, and endpoint specificity.
Foundational biology is not outcome proof. NAD+ is central to metabolism, but intervention claims need direct evidence.
Biomarker changes need interpretation. Raising or changing a marker does not automatically establish performance, longevity, or clinical benefit.
Route and precursor context differ. NAD+ and its precursors can have different evidence questions and should not be collapsed into one claim.
Long-term outcomes remain uncertain. Human data is useful but does not settle durability, population fit, or broad health effects.
Safety context should remain route- and product-specific. Public content should not imply that NAD+ biology makes every intervention risk-free.
Regulatory and quality context matters. Product identity, claims, and oversight can vary widely across NAD+-related offerings.
Longevity language requires restraint. Aging-research pathways are interesting, but they do not justify rejuvenation promises.
NAD+ shows up in performance and longevity discussions because energy metabolism, stress tolerance, and mitochondrial function affect how people think about resilience. The page should not imply that NAD+ is a direct energy solution. It should explain why the biology is relevant and why outcome claims remain more limited.
The practical interpretation is to distinguish NAD+ status, precursor research, route context, and real-world endpoints. Human biomarker studies can be meaningful while still leaving questions about durability, clinical relevance, population fit, and long-term risk.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
Not a longevity guarantee. NAD+ biology does not prove anti-aging or rejuvenation outcomes.
Not a direct energy promise. Cellular energy metabolism should not be translated into assured subjective energy effects.
Not one uniform intervention category. NAD+, precursors, products, and routes should not be treated as interchangeable.
Not a protocol or personal-use guide. This entry is educational only and should not be read as direction for unsupervised use.
Aeternus views NAD+ as a foundational biology entry that needs sober interpretation. It belongs in the library because redox metabolism and mitochondrial signaling are central to performance and longevity education. The right position is to explain the pathway, summarize human and mechanistic evidence, and keep claims tied to measured endpoints rather than aspirational longevity language.
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.
MOTS-C is a mitochondrial-derived peptide research topic discussed around metabolic signaling, stress response, and exercise biology.
MOTS-C is a mitochondrial-derived peptide topic with a strong research narrative and a still-limited human evidence base. It is discussed around metabolic flexibility, AMPK-related signaling, exercise response, and stress adaptation. The public page should make the mitochondrial biology understandable while keeping translation limits visible.
MOTS-C is a short peptide encoded within mitochondrial 12S rRNA and studied as part of the mitochondrial-derived peptide family. It is commonly discussed as a signal that may connect mitochondrial state to nuclear gene expression, metabolic stress response, and whole-body energy regulation. That makes it relevant to performance biology, but not established as a practical performance tool.
The biological context centers on mitochondrial signaling, metabolic flexibility, AMPK-related pathways, insulin-sensitivity research, skeletal-muscle stress response, and exercise adaptation. Those themes are important because mitochondria do more than produce ATP; they also communicate cellular stress and energetic state. MOTS-C is interesting because it sits inside that communication network.
MOTS-C is discussed mechanistically through mitochondrial-nuclear communication, metabolic stress response, AMPK-related signaling, and skeletal-muscle metabolism. The reviewed literature supports this as a research-level pathway conversation. Mechanistic plausibility is meaningful, but it does not establish direct human outcomes.
Some human-adjacent research explores MOTS-C in relation to exercise and metabolic markers, while much of the causal biology remains preclinical. That split should be explicit. The page can explain why the peptide is interesting without implying that it reliably improves metabolism, endurance, or recovery in people.
Human data. The reviewed sources include limited human or human-adjacent discussion, but the direct evidence base is not strong enough for broad outcome claims. Human language should focus on research context, biomarkers, and study limitations rather than practical effects.
Preclinical data. Most causal evidence remains preclinical. Animal and cell work supports discussion of metabolic regulation, stress response, and mitochondrial signaling pathways. Those models help explain the research interest but do not establish confirmed human performance or metabolic outcomes.
Anecdotal discussion. Anecdotal discussion around MOTS-C often centers on energy, metabolism, and exercise resilience. That visibility can explain public interest, but it should not drive the claims. Anecdote is especially weak when product identity, route context, population, and outcome measurement are unclear.
Human outcome evidence remains limited. Mechanistic and preclinical findings do not establish predictable human metabolic or performance results.
Mitochondrial signaling is complex. A pathway involved in stress adaptation can be biologically important without being a practical intervention.
Study endpoints vary. Biomarkers, animal outcomes, and human observations should not be treated as interchangeable.
Long-term safety and product identity remain unresolved. Public discussion should not imply validated access or predictable effects.
Human exposure data remains limited. The reviewed evidence does not support casual or unsupervised framing.
Product quality matters. Emerging peptide topics can be especially vulnerable to identity and purity uncertainty.
Performance language should stay conservative. Mitochondrial mechanisms should not be used to imply assured energy, endurance, or recovery outcomes.
MOTS-C appears in performance conversations because mitochondrial signaling is central to training adaptation, fatigue resistance, substrate use, and metabolic resilience. That does not make the peptide a training solution. It makes it a useful lens for explaining how mitochondria participate in signaling, not just energy production.
The practical interpretation should stay research-first. MOTS-C can be described as a mitochondrial peptide of interest in metabolic and exercise biology, but claims about body composition, endurance, glucose control, or recovery should remain limited to the evidence reviewed.
Across the Aeternus library, the practical standard is claim matching. A mechanism belongs in mechanism language, a cell or animal model belongs in preclinical language, and a human trial belongs in population-specific human-evidence language. This keeps the entry useful for readers who want orientation without turning biology into personal direction. The strongest interpretation is usually the narrowest accurate one: name the pathway, name the evidence type, name the limits, and leave space for uncertainty where the sources do not answer the question. That standard also protects the reader from a common mistake in this category: assuming that biological relevance automatically creates a usable strategy. It does not. Evidence becomes useful when the claim, source type, population, endpoint, and safety context all line up.
Not a validated metabolism solution. MOTS-C should not be framed as an established human metabolic or body-composition tool.
Not an endurance guarantee. Mitochondrial signaling does not prove practical performance effects.
Not a shortcut around fundamentals. Training, nutrition, sleep, stress, and health context still drive adaptation.
Not a protocol or personal-use guide. This entry is educational only and should not be read as direction for unsupervised use.
Aeternus views MOTS-C as a sophisticated mitochondrial-signaling topic that deserves careful public explanation. The biology is interesting because it connects mitochondrial state, stress response, and metabolic adaptation. The evidence is not strong enough for broad practical claims. The right position is curiosity with restraint: explain the signal, separate preclinical from human evidence, and avoid turning mitochondrial language into hype.
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.
